Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 22:46:100603.
doi: 10.1016/j.jbo.2024.100603. eCollection 2024 Jun.

Incidence, Risk Factors, and Survival of Bone Metastases and Skeletal-Related Events in Melanoma Patients: A Systematic Review and Quality Assessment of 29 Studies

Michelle R Shimizu  1 , Olaf N van de Langerijt  2 , Daniel Torres  1 , Tom de Groot  3 , Olivier Q Groot  2
Affiliations
Review

Incidence, Risk Factors, and Survival of Bone Metastases and Skeletal-Related Events in Melanoma Patients: A Systematic Review and Quality Assessment of 29 Studies

Michelle R Shimizu et al. J Bone Oncol. .

Abstract

Background: Skeletal metastases make up 17% of all metastases from advanced-stage melanoma. Bone metastases are associated with increased morbidity and mortality and decreased quality of life due to their association with skeletal-related events (SREs), including pathological fracture, spinal cord compression, hypercalcemia, radiotherapy, and surgery. The study aimed to determine the incidence of bone metastases and SREs in melanoma, identify possible risk factors for the development of bone metastases and SREs, and investigate survival rates in this patient population.

Methods: A computer-based literature search was conducted using Pubmed, Embase, and Cochrane Central Register of Controlled Trials up to July 2023. The Newcastle-Ottawa Quality Assessment Scale (NOS) was utilized for quality assessment. Study characteristics, patient information, risk factors for developing bone metastases and SREs, and characteristics for survival were recorded.

Results: We included 29 studies. The average bone metastasis-free interval ranged from four to 72 months. Incidence of bone metastases varied from 2 % to 49 % across 14 studies. 69 % (20/29) of studies described the location of bone metastases, with 24 % (7/29) focusing solely on spinal metastases. In one study, 129 SREs were recorded in 71 % (59/83) of the patient cohort, with various manifestations. The use of bone-directed agents was independently associated with lower risk of SREs. Survival after detection of bone metastasis ranged from three to 13 months. Factors associated with survival included clinical, tumor-related, and treatment features.

Conclusion: This review highlights the notable prevalence and risk factors of developing bone metastases and subsequent SREs in patients with melanoma. The surge in bone metastases poses a challenge in complication management, given the high prevalence of SREs. While this study offers a comprehensive overview of the incidence, risk factors, and outcomes associated with bone metastases and SREs in melanoma patients that may guide patient and physician decision-making, a notable gap lies in the limited availability of high-quality data and the heterogeneous design of the existing literature. Future research should address predictive factors for bone metastases and SREs in melanoma to facilitate patient and physician decision-making and ultimately improve outcomes in this patient population.

Keywords: Bone metastases; Incidence; Melanoma; Risk factors; Skeletal-related events; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Flowchart of included studies (n = 29).
None
See this image and copyright information in PMC

References

    1. Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of Melanoma. Med Sci (Basel) [Internet]. 2021 Oct 20 [cited 2023 Dec 12];9(4). Available from: https://pubmed-ncbi-nlm-nih-gov.treadwell.idm.oclc.org/34698235/. - PMC - PubMed
    1. Damsky WE, Rosenbaum LE, Bosenberg M. Decoding melanoma metastasis. Cancers (Basel) [Internet]. 2010 Mar [cited 2023 Dec 12];3(1):126–63. Available from: https://pubmed-ncbi-nlm-nih-gov.treadwell.idm.oclc.org/24212610/. - PMC - PubMed
    1. Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer [Internet]. 2018 Jan 6 [cited 2023 Dec 12];18(1). Available from: https://pubmed-ncbi-nlm-nih-gov.treadwell.idm.oclc.org/29306325/. - PMC - PubMed
    1. Zekri J, Marples M, Taylor D, Kandukurti K, McParland L, Brown JE. Complications of bone metastases from malignant melanoma. J Bone Oncol [Internet]. 2017 Sep 1 [cited 2023 Dec 12];8:13–7. Available from: https://pubmed-ncbi-nlm-nih-gov.treadwell.idm.oclc.org/28856087/. - PMC - PubMed
    1. Stewart W.R., Gelberman R.H., Harrelson J.M., Seigler H.F. Skeletal metastases of melanoma. J Bone Joint Surg Am. 1978 Jul;60(5):645–649. - PubMed

LinkOut - more resources